Clinical Trial Update: First in Human Study of IMGN151 in Recurrent Gynaecological Cancers [Phase 1]

View source ↗

Summary

This update covers the first-in-human Phase 1 study of IMGN151 in recurrent gynecologic cancers, sponsored by AbbVie, with the trial status shown as ACTIVE_NOT_…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cervical Cancer
• Endometrial Cancer
• Fallopian Tube Cancer
• High-grade Serous Ovarian Carcinoma
• Peritoneal Carcinoma

Drugs mentioned

• IMGN151

Snippet

Sponsor: AbbVie | Conditions: Endometrial Cancer, High Grade Serous Adenocarcinoma of Ovary | Phase 1 | Status: ACTIVE_NOT_RECRUITING